Thymosin α1, an immune-modulating peptide, may help prevent severe COVID-19 in cancer patients undergoing treatment by boosting their weakened immune defenses.
Phase II trialPROTHYMOS study designed to test thymosin α1 prophylaxis in cancer patients
What the researchers found
Thymosin α1 has a strong theoretical basis for preventing severe COVID-19 in immunocompromised cancer patients, supported by its known immune-modulating properties, leading to a Phase II randomized clinical trial.
Why it matters
Cancer patients face disproportionately high risks from COVID-19 and often mount weaker vaccine responses. A prophylactic peptide therapy could provide an additional layer of protection for this vulnerable population.
The numbers in context
Phase II randomized study; PROTHYMOS (Eudract 2020-006020-13); TA1 for COVID-19 prophylaxis in cancer patients.
How the study worked
Rationale paper describing the scientific basis and design for the PROTHYMOS study, a prospective, multicenter, open-label, Phase II randomized trial.
Who was studied
Cancer patients undergoing active treatment
What this study cannot tell us
This is a rationale paper rather than a results paper — the clinical trial was still in its start-up phase. Actual efficacy data was not yet available.
How to read the evidence
Rationale/protocol paper presenting theoretical basis and trial design without efficacy results. Evidence grade is preliminary.
When this study was published
Published in 2021 during the early COVID-19 vaccine era, when prophylactic options for immunocompromised patients were especially needed.
The bigger picture
Thymosin α1 has a long history of use as an immune modulator in viral infections and cancer. Its potential application in COVID-19 prophylaxis for immunocompromised patients highlights how existing peptide therapies can be repurposed during health emergencies, and results could inform future combination approaches with vaccines.
Questions still open
- Does thymosin α1 actually reduce severe COVID-19 rates in cancer patients in the clinical trial?
- Could thymosin α1 enhance vaccine efficacy in immunocompromised individuals?
- What is the optimal dosing and timing of thymosin α1 for prophylactic use?
Common questions
What is thymosin alpha-1 and how does it work?
Why are cancer patients at higher risk for severe COVID-19?
Read the original research
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients.
Future oncology (London, England), 17(9), 1097-1104
Citation
Bersanelli, Melissa; Giannarelli, Diana; Leonetti, Alessandro; Buti, Sebastiano; Tiseo, Marcello; Nouvenne, Antonio; Ticinesi, Andrea; Meschi, Tiziana; Procopio, Giuseppe; Danielli, Riccardo. (2021). The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients.. Future oncology (London, England), 17(9), 1097-1104. https://doi.org/10.2217/fon-2020-0754